# Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Source: https://onco.cc/trials/nct06358430/  
OnCo record `nct06358430` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.

## Summary

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD). ClinicalTrials.gov record last updated 2026-08-04: active not recruiting. Enrollment is actual at 10 participants. Primary completion is estimated at 2029-01-18. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-06
- Registry id: NCT06358430
- Phase: 1
- Setting: Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 10

## Notes

- ClinicalTrials.gov record last updated 2026-08-04: active not recruiting. Enrollment is actual at 10 participants. Primary completion is estimated at 2029-01-18. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT06358430: https://clinicaltrials.gov/study/NCT06358430

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [TROP2 CAR/IL-15 cord-blood NK cells](https://onco.cc/drugs/trop2-car-il15-cord-blood-nk/)

---
JSON: https://onco.cc/api/v1/entities/nct06358430.json